Rhythm Pharmaceuticals Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Net Product Revenues and Upcoming Milestones
Rhythm Pharmaceuticals Announces Preliminary Data from Exploratory Phase 2 Trial that showed Setmelanotide Demonstrated Positive Efficacy Signal in Prader-Willi Syndrome
Rhythm Pharmaceuticals to Announce Preliminary Data from Exploratory Phase 2 Trial Evaluating Setmelanotide in Prader-Willi Syndrome
Rhythm Pharmaceuticals Announces FDA Extension of Review Period for IMCIVREE® for Patients with Acquired Hypothalamic Obesity
Rhythm Pharmaceuticals Announces Public Reimbursement for IMCIVREE® in Canada in Five Provinces and Under the Federal Non-Insured Health Benefits Program
Tartisan Nickel Corp. Appoints Jack Jacobs, Congressional Medal of Honour Recipient, Retired Army Colonel and Distinguished Business Executive to Board of Advisors
